Maze Therapeutics (NASDAQ:MAZE) Shares Gap Up – Here’s Why

Shares of Maze Therapeutics, Inc. (NASDAQ:MAZE) gapped up before the market opened on Wednesday . The stock had previously closed at $25.69, but opened at $27.33. Maze Therapeutics shares last traded at $27.5810, with a volume of 547,304 shares traded.

Analyst Ratings Changes

Several research firms have weighed in on MAZE. Truist Financial lowered their price objective on Maze Therapeutics from $68.00 to $64.00 and set a “buy” rating on the stock in a research report on Tuesday, April 14th. Weiss Ratings reiterated a “sell (d)” rating on shares of Maze Therapeutics in a research report on Thursday, January 22nd. Guggenheim increased their price objective on Maze Therapeutics from $46.00 to $58.00 and gave the stock a “buy” rating in a research report on Wednesday, March 4th. HC Wainwright increased their price objective on Maze Therapeutics from $60.00 to $110.00 and gave the stock a “buy” rating in a research report on Wednesday, March 25th. Finally, JPMorgan Chase & Co. raised their price target on Maze Therapeutics from $52.00 to $58.00 and gave the stock an “overweight” rating in a research report on Tuesday, March 31st. Two research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $66.00.

Maze Therapeutics Price Performance

The stock has a 50-day simple moving average of $39.72 and a 200-day simple moving average of $38.29. The stock has a market cap of $1.39 billion, a P/E ratio of -8.65 and a beta of 5.16.

Maze Therapeutics (NASDAQ:MAZE) last released its earnings results on Wednesday, March 25th. The company reported ($0.65) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.08. As a group, sell-side analysts forecast that Maze Therapeutics, Inc. will post -2.59 earnings per share for the current year.

Insider Buying and Selling at Maze Therapeutics

In other Maze Therapeutics news, insider Atul Dandekar sold 7,500 shares of Maze Therapeutics stock in a transaction dated Thursday, January 29th. The stock was sold at an average price of $44.27, for a total value of $332,025.00. Following the transaction, the insider owned 10,503 shares in the company, valued at $464,967.81. The trade was a 41.66% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CMO Harold Bernstein sold 30,000 shares of Maze Therapeutics stock in a transaction dated Tuesday, March 10th. The shares were sold at an average price of $50.45, for a total value of $1,513,500.00. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 95,000 shares of company stock worth $4,245,625 over the last 90 days.

Institutional Trading of Maze Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Royal Bank of Canada grew its holdings in shares of Maze Therapeutics by 128.3% during the fourth quarter. Royal Bank of Canada now owns 646 shares of the company’s stock worth $27,000 after purchasing an additional 363 shares during the last quarter. Ameritas Investment Partners Inc. grew its holdings in shares of Maze Therapeutics by 82.6% during the third quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock worth $42,000 after purchasing an additional 738 shares during the last quarter. California State Teachers Retirement System grew its holdings in shares of Maze Therapeutics by 138.0% during the fourth quarter. California State Teachers Retirement System now owns 1,321 shares of the company’s stock worth $55,000 after purchasing an additional 766 shares during the last quarter. Police & Firemen s Retirement System of New Jersey grew its holdings in shares of Maze Therapeutics by 18.5% during the fourth quarter. Police & Firemen s Retirement System of New Jersey now owns 5,961 shares of the company’s stock worth $247,000 after purchasing an additional 931 shares during the last quarter. Finally, GF Fund Management CO. LTD. bought a new stake in shares of Maze Therapeutics during the fourth quarter worth about $39,000.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.